Secondary relevance to vitamin D This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.
This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.
Why this paper is included
Supporting source evidence:
Additionally, PTH levels were significantly higher in patients taking long-term PPIs (p = 0.005), as well as vitamin D3 levels (p = 0.0001).
Source: Results. View original paper
Relevance classification does not establish study quality, causation or editorial approval.
Study design Case-control study.
Case-control study
Compares people with an outcome against people without it, examining exposures.
Meta-analysis unclear · Blinding unclear / not reported · Research setting awaiting verification
How this paper was classified
Automatic source-based classification; awaiting editorial verification. This is not a quality score.
Methods: This is a case-control study including patients treated with PPIs (>1 year) and control subjects who have not received PPIs treatment.
Source: Abstract.
What the study types mean
- Systematic review
- Uses explicit methods to identify, assess and summarise research on a defined question.
- Scoping review
- Maps the extent and characteristics of research on a topic.
- Narrative review
- Discusses existing research; systematic-review methods have not been established by this classification.
- Review / evidence synthesis
- Reviews existing research; the exact review methods need further assessment.
- Randomised controlled trial
- Assigns participants or groups to comparison interventions by chance.
- Non-randomised intervention study
- Examines an intervention without random allocation.
- Cohort study
- Examines exposures and outcomes over time within a defined group.
- Case-control study
- Compares people with an outcome against people without it, examining exposures.
- Cross-sectional study
- Examines a population at a particular point in time.
- Observational study
- Observes exposures and outcomes without assigning the exposure; the subtype is not established here.
- Case report
- Describes an individual case.
- Case series
- Describes a group of individual cases.
- Secondary analysis
- Analyses existing study data; this paper is not automatically another independent trial.
- Laboratory study
- Investigates biological processes in a laboratory setting.
- Qualitative study
- Examines experiences or meanings using qualitative methods.
- Genetic instrumental-variable study
- Uses genetic variation as an instrument to investigate relationships; this is not a randomised treatment trial.
- Study protocol
- Describes planned methods and is not evidence that the planned study has reported results.
- Multiple reported designs
- More than one design is explicitly reported; examine the supporting methods.
- Study design awaiting verification
- The available source does not establish a sufficiently clear study design.
Meta-analysis combines numerical results from studies. Blinding describes who was unaware of treatment allocation. Neither is a separate quality grade. Study design, vitamin D relevance and document format are independent filters.
Abstracts
Effect of long-term proton pump inhibitors on phosphocalcium metabolism and bone mineral density
Case-control study · Future Science OA · 2024
Original publication title
Effect of long-term proton pump inhibitors on phosphocalcium metabolism and bone mineral density
© 2024 Hend Smaoui
Original publication · Publisher record · CC BY 4.0
Source wording retained. Formatting, section navigation and display-title punctuation adapted for this research record.
At a glance
Abstract: What objectives does the paper state?
Although Proton pump inhibitors (PPIs) are well-tolerated, their long-term use may be associated with decreased bone mass.
Source: Aim:Abstract: Results
A total of 90 patients and 90 matched controls were included. PPIs use was associated with hypocalcemia and hypomagnesemia. Vitamin D3 deficiency and hyperparathyroidism were associated with PPIs use. Long-term PPIs use was significantly associated with decreased bone density. Risk factors of decreased bone mineral density (BMD) included age >50 years, menopause, lack of sun exposure, double PPIs dose, daily intake, post-meal intake and association with a mucoprotective agent.
Source: Results:Abstract: Conclusion
Our results highlight the risk of decreased BMD in patients on long-term PPIs treatment.
Source: Conclusion:Authors’ abstract
Aim:
Although Proton pump inhibitors (PPIs) are well-tolerated, their long-term use may be associated with decreased bone mass.
Methods:
This is a case-control study including patients treated with PPIs (>1 year) and control subjects who have not received PPIs treatment.
Results:
A total of 90 patients and 90 matched controls were included. PPIs use was associated with hypocalcemia and hypomagnesemia. Vitamin D3 deficiency and hyperparathyroidism were associated with PPIs use. Long-term PPIs use was significantly associated with decreased bone density. Risk factors of decreased bone mineral density (BMD) included age >50 years, menopause, lack of sun exposure, double PPIs dose, daily intake, post-meal intake and association with a mucoprotective agent.
Conclusion:
Our results highlight the risk of decreased BMD in patients on long-term PPIs treatment.
Plain language summary
In this study, we investigated the impact of long-term use of proton pump inhibitors (PPIs) on bone health. Examining 90 patients on PPIs for over a year and matching them with control subjects, we found that PPIs were linked to lower bone density. Factors such as age over 50. menopause, limited sun exposure, higher PPIs dosage, daily intake, post-meal usage and combining PPIs with a mucoprotective agent were associated with decreased bone mineral density. Our findings emphasize the concern of reduced bone density in individuals undergoing prolonged PPIs treatment.
Summary points
Association with bone health: the clinical trial underscores the well-established association between long-term proton pump inhibitor (PPI) use and adverse effects on bone health, including decreased bone mineral density (BMD).
Risk factors for decreased BMD: the study identifies specific risk factors contributing to reduced BMD in patients on long-term PPI treatment. Notable factors include age over 50 years, menopausal status, lack of sun exposure, double PPI dose, daily intake, post-meal administration, and the concurrent use of mucoprotective agents.
Magnitude of the study: the research encompasses a substantial sample size, involving 90 patients on long-term PPI treatment and 90 matched controls. This robust dataset allows for a comprehensive exploration of various factors influencing bone health.
Biochemical disturbances: the trial meticulously examines phosphocalcic assessment, parathyroid hormone (PTH) levels, 25-hydroxy vitamin D levels, and osteodensitometric data. This detailed biochemical analysis enhances the understanding of the physiological changes associated with PPI use.
Hypomagnesemia and hypocalcemia: the study highlights a significant association between PPI use and hypomagnesemia, contributing to the understanding of the impact of PPIs on magnesium levels.
Age and menopause Impact: the findings underscore the significance of age, particularly those over 50 years, as a critical factor in decreased BMD associated with PPI use. Menopausal status among women is identified as another key determinant of bone health in this context.
Specific PPI conditions: the trial reveals specific conditions under which the risk of bone demineralization is elevated with PPI use. These conditions include regular use, double dose, daily intake, post-meal administration, and combination with a mucoprotective agent.
Multivariate analysis: through multivariate analysis, the study pinpoints that a decrease in BMD is significantly more observed in patients aged over 50 years, even after adjusting for various factors such as age, physical activity, menopause, and PPI treatment modalities.
Caution in prescription: the research calls for a more cautious approach in prescribing PPIs, especially in long-term use and in patients over the age of 50. given the identified risks to bone health. The study suggests that healthcare providers should carefully weigh the potential benefits against the risks associated with prolonged PPI use.
No increase in fracture risk: contrary to some previous studies, this trial does not find an increased risk of vertebral or femoral neck fractures associated with PPI use, emphasizing the complexity of the relationship between PPIs and bone health.
Publication and source details
Original title: Effect of long-term proton pump inhibitors on phosphocalcium metabolism and bone mineral density
Hend Smaoui; Lassaad Chtourou; Dana Jallouli; Samar Ben Jemaa; Iheb Karaa; Mouna Boudabbous; Manel Moalla; Hela Gdoura; Leila Mnif; Ali Amouri; Rim Akrout; Fatma Ayadi; Sofien Baklouti; Nabil Tahri
Future Science OA · 2024
* CONTACT: hanou.smaoui@gmail.com© 2024 Hend Smaoui2024https://creativecommons.org/licenses/by/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The terms on which this article has been published allow the posting of the Accepted Manuscript in a repository by the author(s) or with their consent.Repository JATS snapshot; version as supplied
Source retrieved: 2026-11-11T04:30:30.850209+00:00
DOI: 10.2144/fsoa-2023-0198 · PMC11152587